Holen Sie sich die Stockscreener-App
16.07
5.34%
0.815
Handel nachbörslich:
16.37
0.30
+1.87%
Schlusskurs vom Vortag:
$15.26
Offen:
$15.2
24-Stunden-Volumen:
36,543
Relative Volume:
0.86
Marktkapitalisierung:
$30.08M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-3.34M
KGV:
-5.953
EPS:
-2.6995
Netto-Cashflow:
$-10.54M
1W Leistung:
+14.95%
1M Leistung:
+3.28%
6M Leistung:
+413.09%
1J Leistung:
+215.10%
1-Tages-Spanne:
$15.00
$16.62
1-Wochen-Bereich:
$12.60
$16.62
52-Wochen-Spanne:
$2.88
$18.20
Polyrizon Ltd Stock (PLRZ) Company Profile
Compare PLRZ vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
16.07 | 28.56M | 0 | -3.34M | -10.54M | -2.6995 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Polyrizon Ltd Aktie (PLRZ) Neueste Nachrichten
Polyrizon Ltd. (PLRZ) Surges Over 20% — Key Resistance Level in FocusOpen Trading Community - Newser
PLRZ Technical Analysis | Trend, Signals & Chart Patterns | POLYRIZON LTD (NASDAQ:PLRZ) - ChartMill
Number of shareholders of Polyrizon Ltd. – NASDAQ:PLRZ - TradingView
Polyrizon signs clinical trial agreement with clinical research site for Nasarix - TipRanks
Polyrizon signs first clinical trial agreement for allergy drug By Investing.com - Investing.com India
Polyrizon Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Trial - geneonline.com
Polyrizon signs first clinical trial agreement for allergy drug - Investing.com
Polyrizon Secures First U.S. Clinical Site for NASARIX Allergy Blocker Trial - TipRanks
Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial - The Manila Times
Polyrizon Ltd. Signs Clinical Trial Agreement for NASARIXTM Allergy Blocker Study in Texas - Quiver Quantitative
Polyrizon (Nasdaq: PLRZ) signs first U.S. clinical site for NASARIX PL-14 allergy study - Stock Titan
Nasal spray to block airborne allergens heads to first U.S. allergy trial site - Stock Titan
TradingKey - TradingKey
Polyrizon develops nasal barrier tech to block multiple respiratory viruses amid rising viral threats - Pluang
Nasal barrier tech: how Polyrizon wants to plug gaps before vaccines - Stock Titan
The growth trajectory Polyrizon (PLRZ) is on and where it leads (+15.56%) 2026-05-08Macro Trends - newser.com
PLRZ (Polyrizon) delays full quarterly earnings release, posting no notable stock movement in today’s session.Payout Ratio - newser.com
[EFFECT] Polyrizon Ltd. SEC Filing - Stock Titan
Polyrizon submits amended claims for intranasal drug delivery patent By Investing.com - Investing.com South Africa
Polyrizon submits amended claims for intranasal drug delivery patent - Investing.com UK
Polyrizon amends patent application claims for intranasal drug delivery platform - TipRanks
Polyrizon Expands U.S. Patent Claims for Intranasal Drug Delivery Platform - TipRanks
Polyrizon (Nasdaq: PLRZ) expands U.S. patent claims for intranasal drug delivery platform - Stock Titan
Polyrizon widens U.S. patent bid to cover how nasal drugs stay put - Stock Titan
Polyrizon expands U.S. patent claims for its intranasal drug delivery platform, boosting IP protection. - Pluang
MMCAP, MM Asset Mgmt (PLRZ) joint filing reports 7.3% ownership - Stock Titan
Polyrizon retains Nasdaq listing following hearings panel - MSN
Polyrizon files European patent for intranasal drug delivery tech By Investing.com - Investing.com South Africa
Polyrizon Files European Patent Application for Trap & Target Intranasal Drug Delivery Platform - TipRanks
Polyrizon files European patent for intranasal drug delivery tech - Investing.com
Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform - The Manila Times
Polyrizon Ltd. Files Divisional Patent Application for Advanced Trap & Target Intranasal Drug Delivery Technology - Quiver Quantitative
Polyrizon seeks Europe patent for system designed to keep nasal drugs in place - Stock Titan
Polyrizon signs MOU to acquire up to 20% stake in eVTOL firm Colugo - MSN
Polyrizon, Pheton, AirSculpt: Top 3 Healthcare Stocks With Soaring Weekly Retail Interest - MSN
Polyrizon shares gain on plan to buy majority stake in private aviation company - MSN
Polyrizon Ltd. (PLRZ) registers 499,999 shares for resale under Form F-1 - Stock Titan
Finanzdaten der Polyrizon Ltd-Aktie (PLRZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):